The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF
NCT ID: NCT06973902
Last Updated: 2025-07-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
120 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-07-10
Study Completion Date
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this observational cohort study, which is both retrospective and prospective, is to evaluate the long-term clinical and instrumental response to Cardiac Contractility Modulation (CCM) treatment in adult subjects suffering from symptomatic heart failure (HF) due to systolic left ventricular dysfunction, despite adequate medical therapy. Based on the response to stress echocardiography with preimplantation low-dose Dobutamine, the main questions it aims to answer are:
* What is the proportion of subjects who experience a clinical response to CCM therapy at 12 months (NYHA reduction ≥ 1 class)?
* There was a reduction in the number of hospitalizations, visits to the Emergency Department, and access to day hospital facilities for more than 4 hours compared to the year before the study (e.g., by intravenous infusion of cardiac inotropic drugs)?
* What is the estimated change in the quality-of-life score using the "Quality of Life Questionnaire with Heart Failure - Minnesota" (MLHFQ) between baseline and the end of follow-up?
* What is the change in walking distance between baseline and the end of the follow-up in the walk test (6MWT) (optional)?
* What is the difference in NT-proBNP levels between baseline and the end of follow-up? Participants are already receiving CCM support as part of their regular medical care for heart failure.
* What is the proportion of subjects who experience a clinical response to CCM therapy at 12 months (NYHA reduction ≥ 1 class)?
* There was a reduction in the number of hospitalizations, visits to the Emergency Department, and access to day hospital facilities for more than 4 hours compared to the year before the study (e.g., by intravenous infusion of cardiac inotropic drugs)?
* What is the estimated change in the quality-of-life score using the "Quality of Life Questionnaire with Heart Failure - Minnesota" (MLHFQ) between baseline and the end of follow-up?
* What is the change in walking distance between baseline and the end of the follow-up in the walk test (6MWT) (optional)?
* What is the difference in NT-proBNP levels between baseline and the end of follow-up? Participants are already receiving CCM support as part of their regular medical care for heart failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF)
NCT06580392
Heart Failure
RECRUITING
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
NCT07209098
Heart Failure and Reduced Ejection Fraction
NYHA Class III Heart Failure
RECRUITING
CCM in Heart Failure With Preserved Ejection Fraction
NCT03240237
Heart Failure, Diastolic
COMPLETED
NA
Observational and Prospective Registry on Cardiac Contractility Modulation (CCM) Therapy
NCT04902079
Heart Failure, Systolic
UNKNOWN
Dynamic EchoCardiographic Optimisation REsponse Study
NCT05473481
Heart Failure
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
-Introductory summary When no other therapeutic options are available, CCM can be a helpful complement to treating heart failure, improving quality of life, and prolonging survival. Still, the high cost and availability of implants in qualified centers limit their use.
Then, searching for indicators that maximize the benefit/risk ratio is appropriate. According to the study's proponents, the contractile reserve of the left ventricle assessed by stress echo to low-dose Dobutamine may be among the most promising indicators for this purpose.
Introduction Heart failure (H.F.) has a very poor prognosis in terms of mortality, quality of life, and functional capacity. It is one of the most important cardiovascular diseases in terms of global prevalence and healthcare costs. Despite appropriate medical care, many patients experience frequent hospitalizations and limitations in daily activities (1).
The prevalence of heart failure ranges between 1% and 3% in the general adult population in industrialized countries. It is expected to increase substantially due to the availability of better diagnostic tools and medical treatments that prolong life after diagnosis of HF (2).
The latest international guidelines on the management of reduced ejection fraction H.F. recommend a timely approach with the simultaneous introduction of the four main categories of drugs (ACE inhibitors or ARNIs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors). If drug therapy alone is not sufficient or not well tolerated by the subject, or if there is a disorder in the conduction of the electrical impulse (in particular, a left bundle branch block), it is possible to associate it with electrical therapy, which consists of the implantation of biventricular cardiac devices (pacemakers or defibrillators) that resynchronize cardiac contraction (cardiac resynchronization therapy, CRT). These devices work in close synergy with anti-decompensation drugs to curb the progression of heart failure and, in some cases, restore normal cardiac contractility. Cardiac resynchronization therapy, combined with drug therapy, has been shown to improve survival and quality of life by reducing the symptoms of heart failure, increasing exercise capacity, and enabling subjects to resume many of their daily activities.
Cardiac Contractility Modulation (CCM) CRT is indicated for patients with a large QRS (\>130 ms and evidence of left bundle branch block)3; however, the percentage of individuals who do not respond to CRT varies between studies, usually between 25% and 33% (4). Randomized clinical trials have shown that Cardiac Contractility Modulation (CCM) is a treatment option5 for patients with symptomatic heart failure despite optimized medical therapy and not eligible for CRT. CCM therapy has also been evaluated in patients who have not responded to CRT (6) therapy.
The implanted device for CCM consists of an implantable pulse generator (like a pacemaker) equipped with a transcutaneously rechargeable battery connected to two ventricular leads that transmit high-energy electrical impulses within the absolute refractory period of the myocardial action potential. The device has no pacing or antiarrhythmic functions and is designed to work even in patients already implanted with pacemakers or defibrillators.
The FIX-HF-47, FIX-HF-58,9, and FIX-HF-5C10 trials demonstrated the safety and efficacy of the CCM device concerning the following end-points:
* NYHA classroom improvement.
* Improvement in the quality of life (according to the Minnesota Living with Heart Failure Questionnaire - MLHFQ).
* Improvement in functional capacity at the 6-minute walk test (6MWT).
* Increased peak oxygen consumption (VO2).
* Reduction of cardiovascular death and hospitalizations for heart failure.
The CCM has been shown to improve myocardial contractility (11) by improving cardiomyocyte management of intracellular calcium. It exerts short- and long-term effects and positively modulates cardiac cell gene expression.
The Optimizer Smart system has been approved in countries where the C.E. mark applies since October 3, 2016.
The OPTIMIZER Smart System is indicated for use in patients over 18 who have symptomatic heart failure due to systolic left ventricular dysfunction despite medical and interventional therapy. CCM therapy delivered by the OPTIMIZER system has been shown to improve the clinical status, functional capacity, and quality of life and prevent hospital admissions in symptomatic patients with left heart failure who are carefully selected and followed by cardiologists experienced in the treatment of heart failure (12).
The Optimizer Smart device was FDA-approved on March 21, 2019, for delivering Cardiac Contractility Modulation (CCM) therapy. This approval is unique in that it is the first device to be granted "Breakthrough Device" status by the FDA and to have been included in the FDA's review panel for cardiovascular devices - where it received a unanimous recommendation for approval due to its favorable benefit/risk ratio and then obtained PMA approval by the FDA (12).
In the 2021 ESC guidelines for diagnosing and treating acute and chronic heart failure (13), CCM is an "under evaluation" therapy in NYHA class III/IV patients, with LVEF between 25% and 45% and QRS duration \<130 ms.
In the consensus paper published in 2024 by the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)(14), CCM is suggested as a therapy that experienced operators who cooperate in a multidisciplinary team for heart failure should consider if symptoms persist.
It has been evaluated that, for heart failure patients with reduced ejection fraction, the addition of CCM therapy could be more convenient than OMT alone (i.e., the combined use of five classes of drugs that, individually, have already been shown to improve the prognosis of infarcted patients: acetylsalicylic acid, beta-blockers, statins, antagonists of the renin-angiotensin system, and thienopyridines), if a time horizon of the whole life is considered (15, 16).
In selected cases, and when no other therapeutic options are available, CCM can be adjunct in patients who do not respond to CRT29.
In a recent study (30), CCM significantly improved H.F. in patients with reduced ejection fraction (HFrEF), NYHA class III, and moderately prolonged QRS of 120-149 ms.
Pharmacological stress echocardiography Pharmacological stress echocardiography is indicated for the diagnosis and treatment of suspected ischemic heart disease or left ventricular dysfunction of suspected ischemic origin. The examination consists of performing an echocardiogram during the infusion of increasing drug doses that stimulate the sympathetic nervous system, stimulating the heart with an effect similar to physical exertion. The heart reacts with increased contraction force and frequency; sometimes, blood pressure can also increase. The examination helps to recognize the possible presence of stress-induced myocardial ischemia.
Other indications of stress echocardiography include quantifying contractile reserve in cardiomyopathies, evaluating cardiac valvulopathy and congenital heart disease, and evaluating diastolic function and pulmonary hypertension. The main advantages of stress echocardiography are its simplicity, low cost, wide availability, and absence of radiation (17, 18).
The most used drugs in this procedure are Dobutamine or dipyridamole. Dobutamine is a synthetic catecholamine that primarily stimulates β1 adrenergic receptors and, to a lesser extent, α1 and β2 receptors.
The protocol for standard dobutamine examination was defined in the American Society of Echocardiography (ASE) guidelines of 2007 (19). A graduated dobutamine infusion is usually administered at a 5 μg/kg starting dose per minute. The dobutamine infusion aims to achieve a heart rate of 85% of the maximum heart rate predicted for the person's age. The dose of Dobutamine is increased every 3-5 minutes to 10, 20, 30, and finally to 40 μg/kg per minute (20).
On the other hand, the "low-dose" dobutamine stress echocardiography (LDDSE) test is optimal for detecting ischemia and assessing viability by searching for the "biphasic response." A myocardial area increases its contraction at a low dose of inotropic but later becomes hypokinetic or akinetic at higher doses of dobutamine (20).
During the low-dose dobutamine stress echocardiography, the subject is stressed with Dobutamine by standardized incremental infusions of 5, 10, and 20 μg/kg/min. Each infusion dose is administered for a maximum of five minutes (18, 20, 21, 22).
As assessed by low-dose dobutamine stress echo, left ventricular contractile reserve is a helpful marker for predicting functional improvement of the left ventricle and determining long-term prognosis in patients with dilated heart disease (23).
Low-dose dobutamine stress echocardiography has proven to be a simple and effective procedure for selecting patients who are candidates for CRT, having demonstrated the correlation between contractile reserve and response to subsequent resynchronization therapy (24). The assay was also used to quantify the degree of remodeling after CRT (25) therapy.
Many CRT studies have evaluated left ventricular reverse remodeling by echocardiographic testing with low-dose Dobutamine. A positive response criterion is a reduction of left ventricular end-systolic volume (LVESV) greater than or equal to 15% (26, 27, 28).
Then, searching for indicators that maximize the benefit/risk ratio is appropriate. According to the study's proponents, the contractile reserve of the left ventricle assessed by stress echo to low-dose Dobutamine may be among the most promising indicators for this purpose.
Introduction Heart failure (H.F.) has a very poor prognosis in terms of mortality, quality of life, and functional capacity. It is one of the most important cardiovascular diseases in terms of global prevalence and healthcare costs. Despite appropriate medical care, many patients experience frequent hospitalizations and limitations in daily activities (1).
The prevalence of heart failure ranges between 1% and 3% in the general adult population in industrialized countries. It is expected to increase substantially due to the availability of better diagnostic tools and medical treatments that prolong life after diagnosis of HF (2).
The latest international guidelines on the management of reduced ejection fraction H.F. recommend a timely approach with the simultaneous introduction of the four main categories of drugs (ACE inhibitors or ARNIs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors). If drug therapy alone is not sufficient or not well tolerated by the subject, or if there is a disorder in the conduction of the electrical impulse (in particular, a left bundle branch block), it is possible to associate it with electrical therapy, which consists of the implantation of biventricular cardiac devices (pacemakers or defibrillators) that resynchronize cardiac contraction (cardiac resynchronization therapy, CRT). These devices work in close synergy with anti-decompensation drugs to curb the progression of heart failure and, in some cases, restore normal cardiac contractility. Cardiac resynchronization therapy, combined with drug therapy, has been shown to improve survival and quality of life by reducing the symptoms of heart failure, increasing exercise capacity, and enabling subjects to resume many of their daily activities.
Cardiac Contractility Modulation (CCM) CRT is indicated for patients with a large QRS (\>130 ms and evidence of left bundle branch block)3; however, the percentage of individuals who do not respond to CRT varies between studies, usually between 25% and 33% (4). Randomized clinical trials have shown that Cardiac Contractility Modulation (CCM) is a treatment option5 for patients with symptomatic heart failure despite optimized medical therapy and not eligible for CRT. CCM therapy has also been evaluated in patients who have not responded to CRT (6) therapy.
The implanted device for CCM consists of an implantable pulse generator (like a pacemaker) equipped with a transcutaneously rechargeable battery connected to two ventricular leads that transmit high-energy electrical impulses within the absolute refractory period of the myocardial action potential. The device has no pacing or antiarrhythmic functions and is designed to work even in patients already implanted with pacemakers or defibrillators.
The FIX-HF-47, FIX-HF-58,9, and FIX-HF-5C10 trials demonstrated the safety and efficacy of the CCM device concerning the following end-points:
* NYHA classroom improvement.
* Improvement in the quality of life (according to the Minnesota Living with Heart Failure Questionnaire - MLHFQ).
* Improvement in functional capacity at the 6-minute walk test (6MWT).
* Increased peak oxygen consumption (VO2).
* Reduction of cardiovascular death and hospitalizations for heart failure.
The CCM has been shown to improve myocardial contractility (11) by improving cardiomyocyte management of intracellular calcium. It exerts short- and long-term effects and positively modulates cardiac cell gene expression.
The Optimizer Smart system has been approved in countries where the C.E. mark applies since October 3, 2016.
The OPTIMIZER Smart System is indicated for use in patients over 18 who have symptomatic heart failure due to systolic left ventricular dysfunction despite medical and interventional therapy. CCM therapy delivered by the OPTIMIZER system has been shown to improve the clinical status, functional capacity, and quality of life and prevent hospital admissions in symptomatic patients with left heart failure who are carefully selected and followed by cardiologists experienced in the treatment of heart failure (12).
The Optimizer Smart device was FDA-approved on March 21, 2019, for delivering Cardiac Contractility Modulation (CCM) therapy. This approval is unique in that it is the first device to be granted "Breakthrough Device" status by the FDA and to have been included in the FDA's review panel for cardiovascular devices - where it received a unanimous recommendation for approval due to its favorable benefit/risk ratio and then obtained PMA approval by the FDA (12).
In the 2021 ESC guidelines for diagnosing and treating acute and chronic heart failure (13), CCM is an "under evaluation" therapy in NYHA class III/IV patients, with LVEF between 25% and 45% and QRS duration \<130 ms.
In the consensus paper published in 2024 by the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)(14), CCM is suggested as a therapy that experienced operators who cooperate in a multidisciplinary team for heart failure should consider if symptoms persist.
It has been evaluated that, for heart failure patients with reduced ejection fraction, the addition of CCM therapy could be more convenient than OMT alone (i.e., the combined use of five classes of drugs that, individually, have already been shown to improve the prognosis of infarcted patients: acetylsalicylic acid, beta-blockers, statins, antagonists of the renin-angiotensin system, and thienopyridines), if a time horizon of the whole life is considered (15, 16).
In selected cases, and when no other therapeutic options are available, CCM can be adjunct in patients who do not respond to CRT29.
In a recent study (30), CCM significantly improved H.F. in patients with reduced ejection fraction (HFrEF), NYHA class III, and moderately prolonged QRS of 120-149 ms.
Pharmacological stress echocardiography Pharmacological stress echocardiography is indicated for the diagnosis and treatment of suspected ischemic heart disease or left ventricular dysfunction of suspected ischemic origin. The examination consists of performing an echocardiogram during the infusion of increasing drug doses that stimulate the sympathetic nervous system, stimulating the heart with an effect similar to physical exertion. The heart reacts with increased contraction force and frequency; sometimes, blood pressure can also increase. The examination helps to recognize the possible presence of stress-induced myocardial ischemia.
Other indications of stress echocardiography include quantifying contractile reserve in cardiomyopathies, evaluating cardiac valvulopathy and congenital heart disease, and evaluating diastolic function and pulmonary hypertension. The main advantages of stress echocardiography are its simplicity, low cost, wide availability, and absence of radiation (17, 18).
The most used drugs in this procedure are Dobutamine or dipyridamole. Dobutamine is a synthetic catecholamine that primarily stimulates β1 adrenergic receptors and, to a lesser extent, α1 and β2 receptors.
The protocol for standard dobutamine examination was defined in the American Society of Echocardiography (ASE) guidelines of 2007 (19). A graduated dobutamine infusion is usually administered at a 5 μg/kg starting dose per minute. The dobutamine infusion aims to achieve a heart rate of 85% of the maximum heart rate predicted for the person's age. The dose of Dobutamine is increased every 3-5 minutes to 10, 20, 30, and finally to 40 μg/kg per minute (20).
On the other hand, the "low-dose" dobutamine stress echocardiography (LDDSE) test is optimal for detecting ischemia and assessing viability by searching for the "biphasic response." A myocardial area increases its contraction at a low dose of inotropic but later becomes hypokinetic or akinetic at higher doses of dobutamine (20).
During the low-dose dobutamine stress echocardiography, the subject is stressed with Dobutamine by standardized incremental infusions of 5, 10, and 20 μg/kg/min. Each infusion dose is administered for a maximum of five minutes (18, 20, 21, 22).
As assessed by low-dose dobutamine stress echo, left ventricular contractile reserve is a helpful marker for predicting functional improvement of the left ventricle and determining long-term prognosis in patients with dilated heart disease (23).
Low-dose dobutamine stress echocardiography has proven to be a simple and effective procedure for selecting patients who are candidates for CRT, having demonstrated the correlation between contractile reserve and response to subsequent resynchronization therapy (24). The assay was also used to quantify the degree of remodeling after CRT (25) therapy.
Many CRT studies have evaluated left ventricular reverse remodeling by echocardiographic testing with low-dose Dobutamine. A positive response criterion is a reduction of left ventricular end-systolic volume (LVESV) greater than or equal to 15% (26, 27, 28).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Symptomatic Congestive Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DeltaESV>=15%
Subjects showing a reduction of 15% or more in LVESV through pre-implant low-dose dobutamine echocardiography stress testing
Cardiac Contractility Modulation (CCM) implant
Intervention Type
DEVICE
Subjects participating in the study carry or will carry the Cardiac Contractility Modulation (CCM) medical device "OPTIMIZER Smart Mini" by Impulse Dynamics (USA). It is indicated for use in patients over 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction, despite appropriate medical treatment.
The OPTIMIZER Smart Mini Implantable Pulse Generator is a programmable device with an internal battery and telemetry functions.
The OPTIMIZER Smart Mini is connected to two or three implantable leads, two of which are implanted in the right ventricle and one, optionally, in the right atrium.
DeltaESV<15%
Subjects showing a reduction of less than 15% in LVESV through pre-implant low-dose dobutamine echocardiography stress testing
Cardiac Contractility Modulation (CCM) implant
Intervention Type
DEVICE
Subjects participating in the study carry or will carry the Cardiac Contractility Modulation (CCM) medical device "OPTIMIZER Smart Mini" by Impulse Dynamics (USA). It is indicated for use in patients over 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction, despite appropriate medical treatment.
The OPTIMIZER Smart Mini Implantable Pulse Generator is a programmable device with an internal battery and telemetry functions.
The OPTIMIZER Smart Mini is connected to two or three implantable leads, two of which are implanted in the right ventricle and one, optionally, in the right atrium.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac Contractility Modulation (CCM) implant
Subjects participating in the study carry or will carry the Cardiac Contractility Modulation (CCM) medical device "OPTIMIZER Smart Mini" by Impulse Dynamics (USA). It is indicated for use in patients over 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction, despite appropriate medical treatment.
The OPTIMIZER Smart Mini Implantable Pulse Generator is a programmable device with an internal battery and telemetry functions.
The OPTIMIZER Smart Mini is connected to two or three implantable leads, two of which are implanted in the right ventricle and one, optionally, in the right atrium.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject of both sexes with age ≥ 18 years,
* Ability to understand and sign informed consent to participate in the study and consent to process sensitive personal data.
* Carrier of symptomatic heart failure, despite optimal medical therapy (OMT),
* Reduced left ventricular systolic function (E.F. \<50%),
* It was positively evaluated for implanting a system for cardiac contractility modulation (CCM) (according to the European Society of Cardiology 2021 Guidelines on heart failure and the provisions of the C.E. mark approval)13.
* Have presented at least one hospitalization, access to the Emergency Department, or access to day hospital facilities for more than 4 hours (e.g., by intravenous infusion of cardiac inotropic drugs) in the year before implantation
* Ability to understand and sign informed consent to participate in the study and consent to process sensitive personal data.
* Carrier of symptomatic heart failure, despite optimal medical therapy (OMT),
* Reduced left ventricular systolic function (E.F. \<50%),
* It was positively evaluated for implanting a system for cardiac contractility modulation (CCM) (according to the European Society of Cardiology 2021 Guidelines on heart failure and the provisions of the C.E. mark approval)13.
* Have presented at least one hospitalization, access to the Emergency Department, or access to day hospital facilities for more than 4 hours (e.g., by intravenous infusion of cardiac inotropic drugs) in the year before implantation
Exclusion Criteria
* Life expectancy \< 1 year due to non-cardiac comorbidities that reduce prognosis,
* Presence of contraindications to the CCM implantation procedure (absence of vascular access usable for CCM implantation, active infectious processes, active severe coagulopathies, presence of mechanical tricuspid valve),
* Contraindications to the performance of the echocardiographic test under pharmacological stress (heart failure in progress, myocardial infarction in the acute phase, acute inflammatory processes of the heart muscle and/or pericardium, critical aortic valve stenosis and severe obstructions to left ventricular outflow, dissecting aneurysm of the aorta, severe arrhythmias not controlled by therapy, known hypersensitivity to the drug, intraventricular thrombi).
* Presence of contraindications to the CCM implantation procedure (absence of vascular access usable for CCM implantation, active infectious processes, active severe coagulopathies, presence of mechanical tricuspid valve),
* Contraindications to the performance of the echocardiographic test under pharmacological stress (heart failure in progress, myocardial infarction in the acute phase, acute inflammatory processes of the heart muscle and/or pericardium, critical aortic valve stenosis and severe obstructions to left ventricular outflow, dissecting aneurysm of the aorta, severe arrhythmias not controlled by therapy, known hypersensitivity to the drug, intraventricular thrombi).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Impulse Dynamics
INDUSTRY
Sponsor Role
collaborator
Quovadis Associazione
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesco Zanon, MD
Role: STUDY_CHAIR
UO Cardiologia, S. Maria della Misericordia Hospital, ULSS5 Polesana, Rovigo (I)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PO Anastasia Guerriero, Marcianise (CE), UOC Cardiologia
Marcianise, Campania, Italy
Site Status
RECRUITING
Clinica Montevergine, Mercogliano (AV), Laboratorio di Elettrofisiologia
Mercogliano, Campania, Italy
Site Status
RECRUITING
UOC Cardiologia, Osp. San Rocco, Sessa Aurunca (CE), ASL Caserta
Sessa Aurunca, Campania, Italy
Site Status
RECRUITING
Policlinico S.Orsola, UO Cardiologia
Bologna, Emilia-Romagna, Italy
Site Status
RECRUITING
OSPEDALE CASTELLI, UO Cardiologia
Anzio, Lazio, Italy
Site Status
RECRUITING
Elettrofisiologia e Aritmologia, ASST FBF Sacco
Milan, Lombardy, Italy
Site Status
RECRUITING
Fondazione Giglio, Cefalù (PA), UOC Cardiologia
Cefalù, Sicily, Italy
Site Status
RECRUITING
Osp. Generale Provinciale Mazzoni, UO Cardiologia
Ascoli Piceno, The Marches, Italy
Site Status
ACTIVE_NOT_RECRUITING
UOC Cardiologia, Osp. Di Mirano, ULSS 3 Serenissima
Mirano, Veneto, Italy
Site Status
RECRUITING
UOC Cardiologia, Osp. Di Piove di Sacco (PD), ULSS 6 Euganea
Piove di Sacco, Veneto, Italy
Site Status
RECRUITING
UOC Cardiologia, Osp. S.Bortolo, Vicenza, ULSS 8 Berica
Vicenza, Veneto, Italy
Site Status
RECRUITING
UOC Cardiologia con UTIC, Osp. Di Venere
Bari, , Italy
Site Status
RECRUITING
UO Cardiologia, S. Maria della Misericordia Hospital, ULSS5 Polesana
Rovigo, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rector, T., S. Kubo, and J. Cohn, Patient's self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire. Heart Failure. Heart Failure, 1987; 1:198-209
Reference Type
BACKGROUND
Nagele H, Behrens S, Eisermann C. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Europace. 2008 Dec;10(12):1375-80. doi: 10.1093/europace/eun257. Epub 2008 Sep 5.
Reference Type
BACKGROUND
Matsumura Y, Takata J, Kitaoka H, Hamada T, Okawa M, Kubo T, Doi Y. Low-dose dobutamine stress echocardiography predicts the improvement of left ventricular systolic function and long-term prognosis in patients with idiopathic dilated cardiomyopathy. J Med Ultrason (2001). 2006 Mar;33(1):17-22. doi: 10.1007/s10396-005-0061-z.
Reference Type
BACKGROUND
Pellikka PA, Nagueh SF, Elhendy AA, Kuehl CA, Sawada SG; American Society of Echocardiography. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr. 2007 Sep;20(9):1021-41. doi: 10.1016/j.echo.2007.07.003. No abstract available.
Reference Type
BACKGROUND
Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, Voigt JU, Zamorano JL; European Association of Echocardiography. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr. 2008 Jul;9(4):415-37. doi: 10.1093/ejechocard/jen175.
Reference Type
BACKGROUND
Narducci ML, Nurchis MC, Ballacci F, Giordano F, Calabro GE, Massetti M, Crea F, Aspromonte N, Damiani G. Cost-utility of cardiac contractility modulation in patients with heart failure with reduced ejection fraction in Italy. ESC Heart Fail. 2024 Feb;11(1):229-239. doi: 10.1002/ehf2.14538. Epub 2023 Nov 9.
Reference Type
BACKGROUND
Witte K, Hasenfuss G, Kloppe A, Burkhoff D, Green M, Moss J, Peel A, Mealing S, Durand Zaleski I, Cowie MR. Cost-effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration. ESC Heart Fail. 2019 Dec;6(6):1178-1187. doi: 10.1002/ehf2.12526.
Reference Type
BACKGROUND
Mullens W, Dauw J, Gustafsson F, Mebazaa A, Steffel J, Witte KK, Delgado V, Linde C, Vernooy K, Anker SD, Chioncel O, Milicic D, Hasenfuss G, Ponikowski P, von Bardeleben RS, Koehler F, Ruschitzka F, Damman K, Schwammenthal E, Testani JM, Zannad F, Bohm M, Cowie MR, Dickstein K, Jaarsma T, Filippatos G, Volterrani M, Thum T, Adamopoulos S, Cohen-Solal A, Moura B, Rakisheva A, Ristic A, Bayes-Genis A, Van Linthout S, Tocchetti CG, Savarese G, Skouri H, Adamo M, Amir O, Yilmaz MB, Simpson M, Tokmakova M, Gonzalez A, Piepoli M, Seferovic P, Metra M, Coats AJS, Rosano GMC. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2024 Feb;26(2):483-501. doi: 10.1002/ejhf.3150. Epub 2024 Jan 25.
Reference Type
BACKGROUND
Authors/Task Force Members:; McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022 Jan;24(1):4-131. doi: 10.1002/ejhf.2333.
Reference Type
BACKGROUND
Borggrefe M, Burkhoff D. Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure. Eur J Heart Fail. 2012 Jul;14(7):703-12. doi: 10.1093/eurjhf/hfs078. Epub 2012 Jun 12.
Reference Type
BACKGROUND
Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuss G. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018 Oct;6(10):874-883. doi: 10.1016/j.jchf.2018.04.010. Epub 2018 May 10.
Reference Type
BACKGROUND
Abraham WT, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Kadish A; FIX-HF-5 Investigators and Coordinators. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail. 2011 Sep;17(9):710-7. doi: 10.1016/j.cardfail.2011.05.006. Epub 2011 Jun 22.
Reference Type
BACKGROUND
Kadish A, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Abraham WT. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011 Feb;161(2):329-337.e1-2. doi: 10.1016/j.ahj.2010.10.025.
Reference Type
BACKGROUND
Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, Misier AR, Curnis A, Bocker D, Remppis A, Kautzner J, Stuhlinger M, Leclerq C, Taborsky M, Frigerio M, Parides M, Burkhoff D, Hindricks G. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008 Apr;29(8):1019-28. doi: 10.1093/eurheartj/ehn020. Epub 2008 Feb 12.
Reference Type
BACKGROUND
Campbell CM, Kahwash R, Abraham WT. Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. Future Cardiol. 2020 Jan;16(1):13-25. doi: 10.2217/fca-2019-0044. Epub 2019 Dec 9.
Reference Type
BACKGROUND
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi: 10.1093/cvr/cvac013.
Reference Type
BACKGROUND
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002 Oct 31;347(18):1397-402. doi: 10.1056/NEJMoa020265.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PREDICT-CCM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
SYNCHRO. Evaluation of the Forecasts Parameters of Real Time-three-dimensional Doppler Echocardiography in Selecting Patients With Chronic Heart Failure for Cardiac Resynchronisation Therapy
NCT00488410
COMPLETED
NA
Clinical Efficacy of Remote Monitoring in the Management of Heart Failure
NCT01723865
COMPLETED
Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure
NCT02857309
TERMINATED
NA
Restore Myocardial Function With CorMatrix® ECM® Particulate (P-ECM)
NCT02139189
COMPLETED
NA
Coronary Sinus Reducer For The Management Of Symptomatic Heart Failure
NCT07057323
ENROLLING_BY_INVITATION
NA
Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study
NCT00821938
COMPLETED
PHASE4
Performance and Safety of the Cardiac Microcurrent Therapy System
NCT04662034
COMPLETED
NA
TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients
NCT00345592
COMPLETED
PHASE4
Cardiac Neuromodulation for Heart Failure
NCT04573699
UNKNOWN
MultiPoint Pacing Programming Guided by Noninvasive Hemodynamics
NCT02064751
COMPLETED
NA
Post-market Prospective, Multicenter, Randomized and Single-blinded Clinical Investigation to Evaluate Whether Cardiac Re-Synchronization Therapy (CRT) Using Automatic Continuous Atrioventricular (AV) Delay Optimization is Superior to CRT With Conventional Biventricular Stimulation (BiV).
NCT06044597
NOT_YET_RECRUITING
NA
Conduction System Pacing Versus Biventricular Pacing for Cardiac ResYNChronization
NCT05155865
COMPLETED
NA
Triple-site Biventricular Stimulation in the Optimization of CRT
NCT02350842
COMPLETED
NA
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
NCT02698241
TERMINATED
NA
Corheart 6: Long-term Cohort Study
NCT07094919
RECRUITING
NA
Cardiac Resynchronization Therapy Modular Registry
NCT01573091
COMPLETED
Arrythmia Burden in Cardiac Contractility Modulation (CCM)
NCT05704426
TERMINATED
Prognostic Value of BNP in MCS - a 25 Year Follow up Study
NCT04377854
RECRUITING
SVC Occlusion in Subjects With Acute Decompensated Heart Failure
NCT03836079
COMPLETED
NA
Myocardial Work and Metabolism in CRT
NCT02537782
UNKNOWN
NA
Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implantation of Defibrillators in Dilated Cardiomyopathy
NCT01378572
UNKNOWN
CRT-P or CRT-D in Dilated Cardiomyopathy
NCT04139460
NOT_YET_RECRUITING
NA
Utility of Tissue Doppler Echocardiography for Selecting Patients for Cardiac Resynchronisation Therapy
NCT01100918
COMPLETED
PHASE4
Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead
NCT06920030
RECRUITING
NA
Moderato System in Patients With Hypertension
NCT03757377
UNKNOWN
NA